Phase 2 N=66 Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)
Malaria
Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=63 Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Thyroid Cancer · Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · HRAS Mutant Tumor
Primary: Antitumor Activity by Objective Response Rate (ORR) — 0.0; 0.0; 43.5; 28.6 percentage of participants
Phase 2 N=46 Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil
Healthy
Primary: Tolerance to Simulated Hemorrhage — 599; 651 min*mmHg
Phase 2 N=50 FLT-PET Imaging of Brain Tumors in Children
Brain Neoplasms
Primary: [18F] Fluorothymidine ([18F]-FLT) Uptake as a Marker of Cellular Proliferation — 1.57; 3.00 SUV max — p=< 0.001
Phase 2 N=51 Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma
Hypertension · Osteonecrosis · Osteonecrosis Due to Drug
Primary: Extensive Radiographic Osteonecrosis — 20; 21; 1; 2 Participants — p=0.7139
Phase 2 N=76 Safety and Efficacy Study of MT-2990 in Women With Endometriosis
Endometrial Related Pain
Primary: Mean Change From Baseline to Week 16 in Nonmenstrual Pelvic Pain Using a Pain Scale Ranges From 0 (None) to 3 (Severe) — -0.28; -0.63 units on a scale
Phase 2 N=130 A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Tumors
Primary: Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
Phase 2 N=80 Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Facioscapulohumeral Muscular Dystrophy (FSHD)
Primary: Change From Baseline in Double Homeobox 4 (DUX4) Activity in Affected Skeletal Muscle — 0.8292; 0.4008 Delta threshold cycle (Ct) — p=0.5621
Phase 2 N=60 Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia
Primary: Platelet Response — 12; 14; 4 Participants
Phase 2 N=203 Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
Invasive Fungal Infections
Primary: Data Review Committee (DRC) Adjudicated Overall Response at Day 42 — 28.7 Response rate percentage
Phase 2 N=471 A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
Hepatitis B, Chronic
Primary: Percentage of Participants Meeting the Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at Week 48 — 9.4; 19.1; 16.3; 5.5 Percentage of participants — p== 0.848
Phase 2 N=6 Anti-malaria MAb in Malian Children
Plasmodium Falciparum Infection · Malaria
Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants
Phase 2 N=599 A Phase 2b Diabetic Kidney Disease Study
Diabetic Kidney Disease
Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338
Phase 2 N=24 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
Breast Cancer
Primary: Change in Ki-67 in Breast Tissue of High-Risk Women
Phase 2 N=105 A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
Rheumatoid Arthritis
Primary: Change in Clinical Disease Activity Index (CDAI) — 18; 17; 12 Participants